Most patients with cancer demonstrated antibody responses to COVID-19 vaccination after two doses of the mRNA-1273 vaccine, according to an observational study published in JAMA Oncology.
The vaccine conferred substantially higher antibody levels among patients seropositive before vaccination, with higher rates of seroconversion among those with solid tumor cancers vs. hematologic malignancies, researchers from the Moffitt Cancer Center reported.
“Maybe a little bit surprisingly, the vast majority of patients were able to mount an antibody response to the vaccine after the second dose,”